

July 8, 2019

Vjuvenate, LLC Karyn Eilber President, CEO 3435 Santa Monica Blvd, Suite 107 Santa Monica, CA 90405

Re: K183050

Trade/Device Name: GLISSANT Intimate Lubricant

Regulation Number: 21 CFR 884.5300

Regulation Name: Condom

Regulatory Class: II Product Code: NUC Dated: May 31, 2019 Received: June 7, 2019

## Dear Karyn Eilber:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm</a> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part

801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <a href="https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products">https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products</a>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <a href="https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems">https://www.fda.gov/medical-device-problems</a>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<a href="https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance</a>) and CDRH Learn (<a href="https://www.fda.gov/training-and-continuing-education/cdrh-learn">https://www.fda.gov/training-and-continuing-education/cdrh-learn</a>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<a href="https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice</a>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Sharon Andrews
Assistant Division Director
DHT3B: Division of Reproductive,
Gynecology and Urology Devices
OHT3: Office of Gastrorenal, ObGyn,
General Hospital and Urology Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

# DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

## Indications for Use

510(k) Number (if known)

Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2020

See PRA Statement below.

.183050	
evice Name LISSANT Intimate Lubricant	
dications for Use (Describe) GLISSANT Intimate Lubricant Fragrance Free/Sea Salt & Car pplication, intended to moisturize and lubricate, and to enhan applement the body's natural lubrication. This product is comolyurethane condoms.	ce the ease and comfort of intimate sexual activity and
rpe of Use (Select one or both, as applicable)	
Prescription Use (Part 21 CFR 801 Subpart D)	Over-The-Counter Use (21 CFR 801 Subpart C)

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

# **GLISSANT Intimate Lubricant – K183050**

# 510(k) Summary

G 1 '44	VHIVENATE LLC		
Submitter	VJUVENATE, LLC		
	3435 Ocean Park Boulevard, Suite 107		
	Santa Monica, CA 90405		
	(424) 835-4372		
Contact person	Karyn S. Eilber, MD		
	dreilber@vjuvenateyou.com		
	(424) 835-4372 Office		
	(310) 909-4967 Mobile		
Date prepared	July 5, 2019		
Device trade names	GLISSANT Intimate Lubricant		
	GLISSANT Intimate Lubricant – Fragrance Free		
	GLISSANT Intimate Lubricant – Sea Salt & Caramel		
Device common name	Personal lubricant		
Regulation number	21 CFR 884.5300		
Regulation name	Condom		
Regulatory class	Class II		
Product code	NUC		
Classification panel	Obstetrics/gynecology		
_			
Predicate device	Aloe Cadabra® Personal Lubricant and Aloe Cadabra®		
	Flavored/Scented Personal Lubricants (K124044)		
	The predicate device has not been subject to a design related recall.		
Indications for use	GLISSANT Intimate Lubricant Fragrance Free/Sea Salt & Caramel		
	is a personal lubricant, for penile and/or vaginal application,		
	intended to moisturize and lubricate, and to enhance the ease and		
	comfort of intimate sexual activity and supplement the body's		
	natural lubrication. This product is compatible with natural rubber		
	latex, polyisoprene, and polyurethane condoms.		
Device description	GLISSANT Intimate Lubricant is a water-based, non-sterile,		
Device description			
	colorless, viscous personal lubricant. It does not contain a		

contraceptive or spermicidal component. The device is packaged in
a polyethylene bottle with a lockdown pump. The primary
packaging is plastic placed inside of a display box (dimensions
1.375" width x 1.375" depth x 4.75" height).

The device specifications are listed in the table below:

Parameter	Specification acceptance criteria
Appearance	Clear, viscous
Color	Colorless
Odor	Odorless
pН	3.9 – 4.1
Specific gravity	1.003 g/mL
Viscosity	250 – 500 cps
Osmolarity	160 - 222 mOsm/kg
Antimicrobial effectiveness	Per USP <51> (Category 2)
Total microbial count	Per USP <61> (<100 cfu/g)
Fungal/yeast/mold limits	Per USP <61> (<10 cfu/g)
Absence of pathogenic	
organisms (e. coli, c. salmonella sp., pseudomonas	Per USP <62> (absent)
aeruginosa, s. aureus, clostridia sp., c. albicans)	

# SUBSTANTIAL EQUIVALENCE DISCUSSION

GLISSANT Intimate Lubricant has the same intended use when compared to the predicate device (Aloe Cadabra® Personal Lubricant and Aloe Cadabra® Flavored/Scented Personal Lubricants (K124044). The GLISSANT Intimate Lubricant has different technological characteristics compared to the predicate device; however, these differences do not raise different questions of safety or effectiveness. The following table compares GLISSANT<sup>TM</sup> Intimate Lubricant to the predicate device.

	DEVICE	PREDICATE DEVICE
	GLISSANT	ALOE CADABRA®
Trade Name	Intimate Lubricant	Personal Lubricant and
	Fragrance free and	Flavored/Scented
	Sea Salt & Caramel	Lubricants
	(K183050)	(K124044)
Regulation number	21 CFR 884.5300	
Regulation name	Condom	SAME
Regulatory class	Class II	
Product code	NUC	
	GLISSANT Intimate	Aloe Cadabra®
Indications for use	Lubricant Fragrance	Lubricant and Aloe
	Free/Sea Salt and Caramel	Cadabra®

	is a personal lubricant, for	Flavored/Scented
	penile and/or vaginal	Lubricants are personal
	application, intended to	lubricants, for penile
	moisturize and lubricate,	and/or vaginal
	and to enhance the ease	application, intended to
	and comfort of intimate	moisturize and lubricate,
	sexual activity and	to enhance the ease and
	supplement the body's	comfort of intimate
	natural lubrication. This	sexual activity and
	product is compatible with	supplement the body's
	natural rubber latex,	natural lubrication. This
	polyisoprene, and	product is compatible
	polyurethane condoms.	with natural rubber latex
	poryuremane condoms.	and polyisoprene
		condoms. This product is
		not compatible with
		polyurethane condoms.
	Water-based, non-sterile,	poryurculane condonis.
Davias description	unscented and	Also bosed non stemile
Device description		Aloe-based, non-sterile, flavored/scented
	flavored/scented personal	
	lubricant	personal lubricant
	Organic aloe barbadensis	
Common ingredients	leaf juice, potassium	Aloe
8	sorbate,	
	hydroxyethylcellulose,	
	stevia, flavor	
Biocompatibility tests	Meets acceptance	
per ISO-10993	requirements for all	SAME
F	biocompatibility tests	~
Condom compatibility	Compatible with natural	Not compatible with
per ASTM D7661-10	rubber latex, polyisoprene,	polyurethane condoms
per morning 27001 10	and polyurethane	pory dictinance condomis
Packaging	PETG plastic bottle with	HDPE plastic bottle with
I ucmagnia	lockdown pump packaged	flip top cap packaged in
	in a carton	a carton
	in a carton	a carton
Shelf life	1 year	2 years
Onen me	1 ,001	2 yours
	Meets acceptance	
Stability tests per USP	requirements for microbial	SAME
<51>, <61>, and <62>	testing at baseline and at 1	DI MILL
~51/, ~01/, and ~02/	year (accelerated aging)	
	year (accelerated aging)	

# SUMMARY OF NON-CLINICAL PERFORMANCE DATA

# **Biocompatibility**

The subject device was evaluated for biocompatibility in accordance with the 2016 FDA guidance document *Use of International Standard ISO 10993-1*, "Biological Evaluation of Medical Devices – Part 1: Evaluation and testing within a risk management process" and ISO 10993-1:2009 as follows:

- Cytotoxicity per ISO 10993-5:2009
- Acute systemic toxicity per ISO 10993-11:2006
- Sensitization per ISO 10993-10:2010
- Vaginal irritation per ISO 10993-10:2010

The results of this testing demonstrated that the subject lubricants are non-cytotoxic, non-irritating, non-sensitizing, and non-systemically toxic.

#### **Condom compatibility**

Condom compatibility was performed according to the FDA recognized consensus standard ASTM D7661-10 *Standard Test Method for Determining Compatibility of Personal Lubricants with Natural Rubber Latex Condoms*. The results of this test indicate that JO subject lubricants are compatible with natural rubber latex, polyisoprene, and polyurethane condoms.

#### **Shelf life (stability) testing**

The shelf life of GLISSANT<sup>TM</sup> Intimate Lubricant is 12 months based on an accelerated aging study per ASTM F1980-16 *Standard Guide for Accelerated Aging of Sterile Barrier Systems for Medical Devices*.

At baseline and following aging, the device met its specifications for appearance, color, odor, pH, specific gravity, viscosity, osmolarity, antimicrobial preservative effectiveness based on USP <51>, total aerobic microbial count and total yeast and mold count based on USP <61>, and absence of pathogenic organisms based on USP <62>.

#### **CONCLUSION**

The results of the performance testing described above demonstrate that the GLISSANT Intimate Lubricants are as safe and effective as the predicate device and support a determination of substantial equivalence.